Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11820732 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GSK3BMAPTATMHIF1A | |
| SCHEMBL11750545 | 0.82 | ALDH1A1 (0.49) | ALDH1A1GSK3BMAPTATMHIF1A | |
| SCHEMBL6486626 | 0.81 | CTNNB1 (0.66) | ALDH1A1MAPTATMMAPK1KDM4E | |
| SCHEMBL1535157 | 0.81 | ATM (0.72) | ALDH1A1MAPTATMMAPK1KDM4E | |
| SCHEMBL10170811 | 0.80 | ALDH1A1 (0.42) | ALDH1A1GSK3BMAPTATMHIF1A | |
| SCHEMBL11753550 | 0.78 | ALDH1A1 (0.43) | ALDH1A1GSK3BMAPTATMHIF1A | |
| SCHEMBL2379710 | 0.77 | CTNNB1 (0.66) | ALDH1A1GSK3BMAPTATMHIF1A | |
| SCHEMBL11550016 | 0.76 | ALDH1A1 (0.54) | ALDH1A1GSK3BMAPTHIF1ATRPA1 | |
| SCHEMBL1928583 | 0.76 | ALOX5 (0.68) | ALDH1A1GSK3BMAPTHIF1ATRPA1 | |
| SCHEMBL11480265 | 0.75 | GSK3B (0.80) | ALDH1A1GSK3BMAPTHIF1ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8889726-B2 | Chemica compounds | GLAXOSMITHKLINE LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889726-B2 | Chemica compounds | GLAXOSMITHKLINE LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889726-B2 | Chemica compounds | GLAXOSMITHKLINE LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140171476-A1 | Chemical Compounds | GLAXOSMITH KLINE LLC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171476-A1 | Chemical Compounds | GLAXOSMITH KLINE LLC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171476-A1 | Chemical Compounds | GLAXOSMITH KLINE LLC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013028953-A1 | COMBINATION TREATMENTS FOR HEPATITIS C | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013022810-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010111534-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | ALDH1A1 1474/4885GSK3B 446/4885MAPT 3989/4885 |
| US-20140171476-A1 | Chemical Compounds | SLC10A1, UGT2B7, CYP3A43 | ALDH1A1 129/4885GSK3B 1312/4885MAPT 2357/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | ALDH1A1 1685/4885GSK3B 422/4885MAPT 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.